RNF41 protein could be a new therapeutic target against cirrhosis and liver inflammation

FHS
July 28, 2023
10:30 pm

The RNF41 protein could be a new therapeutic target in the fight against two chronic liver diseases: cirrhosis and liver inflammation.

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 – Biotech Investments

Issuer: CureVac / Key word(s): Miscellaneous 18.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Report Fourth

April 19, 2024

Smartphone Tests Detect Frontotemporal Dementia

Cognitive tests administered through a smartphone mobile application (app) accurately and reliably detected frontotemporal lobar degeneration (FTLD), also known as frontotemporal dementia (FTD), an observational

April 2, 2024

Lawmakers Push for MDMA Approval; Dogs and Depression; Barriers to OUD Prescribing

A bipartisan group of House and Senate lawmakers is pressuring the Biden administration to approve Lykos Therapeutics’ midomafetamine (MDMA)-assisted treatment for post-traumatic stress disorder; an

August 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.